You have 9 free searches left this month | for more free features.

platinum resistant ovarian cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)

Active, not recruiting
  • Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Minsk, Belarus
    Minsk City Clinical Oncology Center
Jul 27, 2023

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Advanced Solid Tumor, Platinum-resistant Ovarian Cancer Trial (SON-1010)

Not yet recruiting
  • Advanced Solid Tumor
  • Platinum-resistant Ovarian Cancer
  • SON-1010
  • (no location specified)
Mar 10, 2023

Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma Trial in Atlanta (Atovaquone, Biopsy, Computed

Not yet recruiting
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 11, 2023

Ovarian Tumors, Ovarian Diseases Trial (Adebrelimab, Fuzuloparib)

Not yet recruiting
  • Ovarian Neoplasms
  • Ovarian Diseases
  • (no location specified)
Feb 23, 2023

Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • Oral Topotecan Combined With Anlotinib
  • Shanghai, China
    Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
Feb 12, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Pancreatic Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2023

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Ovarian Cancer Trial in Houston (Paclitaxel, Bevacizumab, Lurbinectedin)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2022

Ovarian Cancer Trial in Lexington (Lapatinib and Paclitaxel)

Recruiting
  • Ovarian Cancer
  • Lapatinib and Paclitaxel
  • Lexington, Kentucky
    Markey Cancer Center
Dec 2, 2022

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • olvimulogene nanivacirepvec
  • +3 more
  • Orlando, Florida
    AdventHealth Cancer Institute
Sep 1, 2022

Platinum-resistant Epithelial Ovarian Cancer Trial in Ocala, Mineola (Maveropepimut-S, Cyclophosphamide 50mg)

Recruiting
  • Platinum-resistant Epithelial Ovarian Cancer
  • Maveropepimut-S
  • Cyclophosphamide 50mg
  • Ocala, Florida
  • +1 more
Jul 20, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Ovarian Cancer Trial in Los Angeles (Pembrolizumab, Gemcitabine, Cisplatin)

Completed
  • Ovarian Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Mar 14, 2022

Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Rochester, Helsinki (TILT-123, Pembrolizumab)

Recruiting
  • Platinum-refractory Ovarian Carcinoma
  • Platinum-resistant Ovarian Cancer
  • TILT-123
  • Pembrolizumab
  • Rochester, Minnesota
  • +1 more
Aug 12, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in Santa Monica, Pittsburgh, Houston (TTI-622, Pegylated Liposomal

Recruiting
  • Ovarian Cancer
  • +5 more
  • TTI-622
  • Pegylated Liposomal Doxorubicin
  • Santa Monica, California
  • +4 more
Jul 26, 2022

Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and

Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma Trial in Canton (ACR-368, Gemcitabine,

Recruiting
  • Platinum-resistant Ovarian Cancer
  • +2 more
  • Mobile, Alabama
  • +7 more
Jan 24, 2023

Cancer, Tumor, Solid, Malignant Tumor Trial (OR502, Cemiplimab)

Not yet recruiting
  • Cancer
  • +6 more
  • (no location specified)
Oct 16, 2023